Hyperbaric Oxygen Therapy After Hair Transplantation

Key points

• Evidence specifically examining HBOT after hair transplantation remains limited, and larger well-designed clinical studies are needed.
• There is, however, a strong biological rationale for its use during the early postoperative period, when transplanted follicles are temporarily without a direct blood supply and are establishing new microvascular connections.
• HBOT substantially increases tissue oxygen availability and has established effects on reducing oedema and inflammation, supporting angiogenesis and tissue repair, and enhancing oxygen-dependent immune function.
• These effects are well recognised in wound healing and surgical practice, including the treatment of selected compromised grafts and flaps.
• A 2026 systematic review of 24 studies involving 2,246 patients adds further clinical evidence supporting HBOT in skin flap and graft surgery.¹
• The direct hair-transplant literature is much smaller but encouraging. A randomised study reported reduced early postoperative shedding, itching and folliculitis in patients receiving HBOT after FUE transplantation, although a significant improvement in long-term graft survival has not yet been demonstrated.²
• Current evidence therefore supports HBOT as a biologically rational adjunct to the early recovery process, while its effect on final hair density and long-term transplant outcome remains to be established.

Hair transplantation is both a surgical and a biological process

Whether a procedure uses follicular unit excision (FUE) or follicular unit transplantation (FUT), the final result depends on more than placement technique. Extracted follicular units are temporarily separated from a direct blood supply. After implantation, they pass through an early period of relative hypoxia while oxygen and nutrients are supplied by diffusion and new microvascular connections begin to form. During this period, follicles remain viable but are metabolically vulnerable.³

At the same time, the donor and recipient sites undergo the normal processes of wound healing, with varying degrees of inflammation, redness, swelling, crusting, itching and discomfort.

Surgical technique remains fundamental. Graft handling, hydration, temperature, time outside the body and recipient-site preparation all influence follicular survival.³ However, the biological environment into which those grafts are placed also matters, particularly during the first days while their new blood supply is developing.

This is where the rationale for HBOT becomes relevant.

How HBOT may support the early healing environment

During HBOT, a patient breathes near-pure medical oxygen at a pressure greater than normal atmospheric pressure. This substantially increases the amount of oxygen dissolved in the plasma and raises tissue oxygen levels, allowing oxygen to reach healing tissues even when local circulation is temporarily reduced.⁴

Several established physiological effects of HBOT are particularly relevant to postoperative healing.

Improved oxygen availability. Before a mature local blood supply has developed, increased dissolved oxygen can support metabolically vulnerable tissues and cells.

Reduction in oedema. HBOT increases oxygen carried in the plasma while hyperoxia-induced vasoconstriction reduces capillary leakage. This combination helps maintain tissue oxygenation while reducing oedema and postoperative swelling.^{4 5}

Modulation of inflammation. HBOT reduces excessive inflammatory responses and swelling, helping to protect healing tissues while allowing the normal processes of repair to continue.⁴

Angiogenesis and tissue repair. Repeated HBOT exposures stimulate biological pathways involved in new blood vessel formation and support fibroblast activity, collagen production and tissue repair.^{4 5 6 1} These processes are particularly relevant when healing tissue is establishing or restoring its microcirculation.

Support for immune function. HBOT enhances oxygen-dependent immune function, supporting the body’s natural defence against infection during wound healing.⁴

These are not mechanisms unique to hair transplantation. They form part of the reason HBOT has been used for decades in wound healing and in selected surgical situations where tissue oxygenation, graft viability or recovery is compromised.^{4 5 6 1}

The question is therefore not whether HBOT has physiological effects on oxygenation and wound healing. These effects are well established. The question is how much those effects translate into measurable clinical benefit after hair transplantation.

What does the clinical evidence show?

The direct evidence in hair transplantation remains limited. There is currently no large multicentre randomised trial and no universally established HBOT protocol specifically for hair-transplant recovery.

Nevertheless, there is relevant evidence from both the wider surgical literature and a smaller number of studies specifically involving hair transplantation.

A significant recent addition is the 2026 systematic review by Carter and colleagues examining HBOT in skin flap and graft surgery.¹ The review included 25 reports from 24 studies involving 2,246 patients, comprising 13 randomised controlled trials and 11 non-randomised studies.

Four randomised trials were included in a meta-analysis and demonstrated a statistically significant overall effect favouring HBOT for flap or graft survival and healing. The authors concluded that “A strong recommendation for pre- and postoperative HBOT is warranted” in the clinical settings they reviewed.¹

This is important wider surgical evidence. Hair follicles are not the same as conventional skin grafts or flaps, but transplanted follicular units share an important biological challenge: after transplantation they must survive a period of relative hypoxia before establishing an effective microvascular supply.

The Carter review therefore provides additional clinical support for the broader biological rationale behind using HBOT around procedures in which tissue survival and vascular integration are important.¹

The evidence specifically examining hair transplantation is smaller but encouraging.

The most relevant direct clinical study was published by Fan and colleagues and involved 34 patients undergoing FUE hair transplantation.² Patients were randomised to routine postoperative care or routine care combined with HBOT at 2.0 ATA for 60 minutes daily for seven days.

Patients receiving HBOT experienced less postoperative itching and folliculitis, lower early postoperative hair shedding and greater satisfaction during early recovery.²

One of the most notable findings was early postoperative shedding, reported at 27.6% in the HBOT group compared with 69.1% in the control group.²

At nine months, graft survival was 96.9% in the HBOT group compared with 93.8% in controls. This difference was not statistically significant.² The study therefore provides encouraging evidence regarding early recovery but does not establish that HBOT improves long-term graft survival.

A subsequent scientific commentary discussed the study and the biological mechanisms that could potentially explain these observations, including the anti-inflammatory effects of HBOT and effects on cellular activity within hair follicle dermal papilla cells.⁷

A broader 2024 evidence review examining HBOT in aesthetic medicine also considered the hair-transplant literature.⁸ It similarly identified the reduction in early postoperative shedding while noting that a significant difference in final graft survival had not been demonstrated.

More recently, Giardiello and colleagues reported outcomes from five men receiving HBOT following FUE transplantation.⁹ Treatment began four to six hours after surgery and consisted of six daily 90-minute sessions at 2.4 ATA.

The authors reported rapid resolution of postoperative discomfort, crust resolution within three to five days and graft integration rates of 97% to 99%, with high patient satisfaction and no observed complications.⁹

This was a small uncontrolled clinical report, so it cannot establish how much of the observed recovery was attributable specifically to HBOT. Nevertheless, it adds to the emerging clinical experience and supports further controlled investigation.

Two additional studies published in 2026 provide further biological interest.

A molecular pilot study examined extracted hair grafts from six FUE donors and investigated the effect of HBOT exposure during the graft-holding phase. The researchers identified time-dependent changes in molecular signalling associated with apoptosis, suggesting a potential biological effect on follicular grafts during this vulnerable period.¹⁰

A separate exploratory study involving nine healthy volunteers investigated the effects of a longer course of 50 HBOT sessions on hair and scalp characteristics and reported improvements in several subjective measures, alongside mixed objective findings.¹¹ This was not a postoperative hair-transplant study, but it contributes to the developing research examining the relationship between hyperbaric oxygen exposure and hair biology.

Taken together, the current literature provides an encouraging signal, particularly in relation to early postoperative recovery, shedding, itching, folliculitis, crusting, swelling and patient comfort.

What has not yet been established is whether these early benefits translate into a significant improvement in final graft survival, hair density or long-term cosmetic outcome.

Improving the early recovery experience can itself be clinically valuable, but it should be considered separately from the final transplant result.

HBOT protocols after hair transplantation

There is not yet a single validated HBOT protocol specifically for hair-transplant recovery.

Published studies have used different treatment schedules. The randomised study by Fan and colleagues used 2.0 ATA for 60 minutes daily for seven days, while the more recent clinical report used 2.4 ATA for 90 minutes daily for six days, beginning within several hours of surgery.^{2 9}

The wider flap and graft literature reviewed by Carter and colleagues also includes treatment at therapeutic hyperbaric pressures, commonly within the 2.0 to 2.5 ATA range.¹

The biological rationale favours treatment during the early postoperative period, when transplanted follicles are most dependent on diffusion for oxygen delivery and before new microvascular connections have fully developed.

Published protocols should not simply be applied universally. Treatment should be individually prescribed following medical assessment and, where appropriate, coordinated with the patient’s transplant surgeon.

Safety and medical supervision

HBOT is a medical treatment and should be delivered with appropriate clinical assessment and supervision.

When correctly prescribed and administered, it is generally well tolerated. The most common adverse effects relate to pressure changes in the ears and sinuses.¹²

Patients should undergo appropriate medical screening before treatment, with particular attention to ear and sinus health, pulmonary conditions, medications and recognised contraindications.

Treatment should be delivered under appropriate medical supervision, using medical-grade equipment, defined pressure and oxygen protocols, appropriate monitoring and established hyperbaric safety procedures.

Conclusion

The evidence specifically examining HBOT after hair transplantation remains limited, but the biological rationale is strong and the early clinical findings are encouraging. HBOT has well-established effects on tissue oxygenation, oedema, inflammation, angiogenesis and wound healing, with substantial experience in surgical wound care and compromised grafts and flaps.^{4 5 6 1}

The emerging hair-transplant literature suggests potential benefits during early recovery, including reduced postoperative shedding, itching, folliculitis, crusting and discomfort.^{2 8 9} However, a significant improvement in long-term graft survival or final hair density has not yet been demonstrated.

HBOT can therefore be considered as an adjunct treatment following hair transplantation, provided that patients understand the potential benefits, recognised side effects, limitations of the current evidence and areas of remaining uncertainty. Treatment should be considered on an individual basis and, where appropriate, in consultation with the referring transplant surgeon.

Further well-designed studies are needed to establish the optimal treatment protocol and determine whether the encouraging early recovery findings translate into improved long-term transplant outcomes.

References